Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation

Circ J. 2007 Apr;71(4):617-9. doi: 10.1253/circj.71.617.

Abstract

Background: Because of its side-effects, long-term administration of ticlopidine limits the use of the sirolimus-eluting stent (SES) in Japan.

Methods and results: Side-effects of ticlopidine occurred in 41 (9.3%) of 440 patients who underwent SES implantation. The majority were liver dysfunction (4.5%) and rash (3.6%). One patient died from severe liver dysfunction. Neutropenia occurred in 3 patients (0.7%). It is remarkable that 28% of side-effects occurred >8 weeks after the initiation of ticlopidine.

Conclusions: Ticlopidine has a relative high rate of side-effects. Clopidogrel should be approved for prevention of stent thrombosis as soon as possible.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Aged
  • Blood Vessel Prosthesis Implantation / methods
  • Chemical and Drug Induced Liver Injury
  • Coronary Thrombosis / prevention & control*
  • Dose-Response Relationship, Drug
  • Drug Implants
  • Drug-Related Side Effects and Adverse Reactions
  • Exanthema / chemically induced
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Incidence
  • Japan
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects*
  • Retrospective Studies
  • Sirolimus / administration & dosage*
  • Stents*
  • Ticlopidine / adverse effects*

Substances

  • Drug Implants
  • Immunosuppressive Agents
  • Platelet Aggregation Inhibitors
  • Ticlopidine
  • Sirolimus